ArticleThe Lancet. Respiratory medicine2018

Tezacaftor-ivacaftor is safe and efficacious in patients with cystic fibrosis with Phe508del mutations.

Tony KirbyPubMed ↗Publisher ↗

No numbers read from the abstract.